Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamie Randall

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Problems in Cancer|April 18, 2022
Patient attendance at molecular tumor board: A new means of shared decision making?Timothy Lewis Cannon, Laura Knopp, Hongkun Wang, et al.
The Oncologist|May 31, 2023
Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic CancerAllison L Hunt, Aratara Nutcharoen, Jamie Randall, et al.
NPJ Precision Oncology|September 14, 2024
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancerLaura E Johnston, Jamie Randall, Safae Chouraichi, et al.
NPJ Precision Oncology|March 5, 2026
Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomicsAllison L Hunt, Jamie Randall, Jonathan D Ogata, et al.
Clinical Proteomics|March 21, 2024
Quantitative proteomic analysis of HER2 protein expression in PDAC tumorsJamie Randall, Allison L Hunt, Aratara Nutcharoen, et al.
NPJ Precision Oncology|April 15, 2025
Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boardsAllison L Hunt, Jamie Randall, Mahesh M Mansukhani, et al.
Cancer Epidemiology|May 1, 2026
Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence studyWhitney R Swain, Selena Bonomelli, Laura Johnston, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Problems in Cancer|April 18, 2022
Patient attendance at molecular tumor board: A new means of shared decision making?Timothy Lewis Cannon, Laura Knopp, Hongkun Wang, et al.
The Oncologist|May 31, 2023
Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic CancerAllison L Hunt, Aratara Nutcharoen, Jamie Randall, et al.
NPJ Precision Oncology|September 14, 2024
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancerLaura E Johnston, Jamie Randall, Safae Chouraichi, et al.
NPJ Precision Oncology|March 5, 2026
Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomicsAllison L Hunt, Jamie Randall, Jonathan D Ogata, et al.
Clinical Proteomics|March 21, 2024
Quantitative proteomic analysis of HER2 protein expression in PDAC tumorsJamie Randall, Allison L Hunt, Aratara Nutcharoen, et al.
NPJ Precision Oncology|April 15, 2025
Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boardsAllison L Hunt, Jamie Randall, Mahesh M Mansukhani, et al.
Cancer Epidemiology|May 1, 2026
Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence studyWhitney R Swain, Selena Bonomelli, Laura Johnston, et al.
Pageof 1